Discovery and validation of graft-versus-host disease biomarkers

Blood

Volumn 121, Issue 4, 2013, Pages 585-594

  Paczesny, Sophie ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 1; ELAFIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; LACTOFERRIN; LEUKOTRIENE A4 HYDROLASE; MICRORNA; MICRORNA 21; MICRORNA 25; MONOCYTE CHEMOTACTIC PROTEIN 2; SCATTER FACTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

BIOINFORMATICS; BIOPSY; CAPILLARY ELECTROPHORESIS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GAMMA DELTA T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONOCYTE; MORTALITY; NONRELAPSE MORTALITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REGULATORY T LYMPHOCYTE; REVIEW; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

EID: 84873044177     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-355990     Document Type: Review

References (91)

1. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011; 117(11):3214-3219.
2. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273-278.
3. Gu W, Pepe MS. Estimating the diagnostic likelihood ratio of a continuous marker. Biostatistics. 2011;12(1):87-101.
4. Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst. 2003;95(7):511-515.
5. Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their performance. Epidemiology. 2005;16(5):598-603.
6. Schlatzer DM, Dazard JE, Ewing RM, et al. Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Mol CellProteomics. 2012;11(6): M111015479
7. Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel). 2012;12(3):3359-3369.
8. Ranganathan P, Heaphy CE, Costinean S, et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 2012;119(20):4786-4797.
9. Magenau JM, Qin X, Tawara I, et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010;16(7):907-914.
10. Teshima T, Maeda Y, Ozaki K. Regulatory T cells and IL-17-producing cells in graft-versus-host disease. Immunotherapy. 2011;3(7):833-852.
11. Zinocker S, Sviland L, Dressel R, Rolstad B. Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease. J Leukoc Biol. 2011; 90(1):177-187.
12. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N EnglJ Med. 2011;365(22):2055-2066.
13. Lau J, Sartor M, Bradstock KF, Vuckovic S, Munster DJ, Hart DN. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease. Transplantation. 2007;83(7):839-846.
14. Akhtari M, Giver CR, Ali Z, et al. Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Transfusion. 2010;50(11):2424-2431.
15. Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(1 suppl):S116-S124.
16. Court M, Selevsek N, Matondo M, et al. Toward a standardized urine proteome analysis methodology. Proteomics. 2011;11(6):1160-1171.
17. Rai AJ, Gelfand CA, Haywood BC, et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics. 2005;5(13):3262-3277.
18. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845-867.
19. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, VeenstraTD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics. 2003;2(10):1096-1103.
20. Thongboonkerd V. Recent progress in urinary proteomics. Proteomics Clin Appl. 2007;1(8):780-791.
21. Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol. 2004;15(1):219-227.
22. Tangrea MA, Wallis BS, Gillespie JW, Gannot G, Emmert-Buck MR, Chuaqui RF. Novel proteomic approaches for tissue analysis. Expert Rev Pro-teomics. 2004;1(2):185-192.
23. Hwang SI, Thumar J, Lundgren DH, et al. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene. 2007;26(1):65-76.
24. Kondo T. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB Rep. 2008;41(9):626-634.
25. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol. 2003; 21(3):255-261.
26. Wild D, ed. The Immunoassay Handbook (3rd Ed). Oxford, United Kingdom: Elsevier; 2005.
27. Schweitzer B, Roberts S, Grimwade B, et al. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol. 2002;20(4):359-365.
28. Boja E, Hiltke T, Rivers R, et al. Evolution of clinical proteomics and its role in medicine. J Pro-teome Res. 2011;10(1):66-84.
29. Rodland KD. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem. 2004;37(7):579-583.
30. Srinivasan R, Daniels J, Fusaro V, et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hema-tol. 2006;34(6):796-801.
31. Imanguli MM, Atkinson JC, Harvey KE, et al. Changes in salivary proteome following alloge-neic hematopoietic stem cell transplantation. Exp Hematol. 2007;35(2):184-192.
32. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975; 250(10):4007-4021.
33. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem. 2005;382(3):669-678.
34. Wang H, Clouthier SG, Galchev V, et al. Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics. 2005; 4(5):618-625.
35. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008;321(5895):1493-1495.
36. Faca V, Coram M, Phanstiel D, et al. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res. 2006;5(8):2009-2018.
37. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452(7187):571-579.
38. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-6708.
39. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2(13):13ra12.
40. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allo-geneic hematopoietic stem cell transplantation. Blood. 2004;104(2):340-349.
41. Brewis IA, Brennan P. Proteomics technologies for the global identification and quantification of proteins. Adv Protein Chem Struct Biol. 2010;80: 1-44.
42. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J Mass Spectrom. 2009;44(12):1637-1660.
43. Michalski A, Damoc E, Lange O, et al. Ultra high resolution linear ion trap Orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes. Mol Cell Proteomics. 2012;11(3):O111013698.
44. MacLean B, Eng JK, Beavis RC, McIntosh M. General framework for developing and evaluating database scoring algorithms using the TANDEM search engine. Bioinformatics. 2006;22(22):2830-2832.
45. Rauch A, Bellew M, Eng J, et al. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res. 2006;5(1):112-121.
46. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A. False discovery rate, sensitivity and sample size for microarray studies. Bioinformat-ics. 2005;21(13):3017-3024.
47. Butte A. The use and analysis of microarray data. Nat Rev Drug Discov. 2002;1(12):951-960.
48. Berglund L, Bjorling E, Oksvold P, et al. A ge-necentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteom-ics. 2008;7(10):2019-2027.
49. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and repro-ducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Bio-technol. 2009;27(7):633-641.
50. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(13):1229-1239.
51. Huttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012;4(142):142ra194.
52. Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hemato-poietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012;7(3):229-239.
53. Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant. 1998;21(8): 769-773.
54. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant. 1996;17(2):185-190.
55. Seidel C, Ringdén O, Remberger M. Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation. 2003;76(2): 423-426.
56. Shaiegan M, Iravani M, Babaee G, Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol. 2006; 15(3):223-227.
57. Visentainer JEL, Lieber SR, Persoli LBL, et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol. 2003; 31(11):1044-1050.
58. Abdallah AN, Boiron JM, Attia Y, Cassaigne A, Reiffers J, Iron A. Plasma cytokines in graft vs host disease and complications following bone marrow transplantation. Hematol Cell Ther. 1997; 39(1):27-32.
59. Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008;112(4): 1539-1542.
60. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75(4):1011-1016.
61. Schots R, Kaufman L, Van Riet I, et al. Proinflam-matory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003;17(6):1150-1156.
62. August KJ, Chiang KY, Bostick RM, et al. Bio-markers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant. 2011;46(4):601-604.
63. Paczesny S, Choi SW, Ferrara JL. Acute graft-versus-host disease: new treatment strategies. Curr Opin Hematol. 2009;16(6):427-436.
64. Schots R, Van Riet I, Othman TB, et al. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002; 30(7):441-446.
65. Malone FR, Leisenring WM, Storer BE, et al. Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hemato-poietic cell transplant. Bone Marrow Transplant. 2007;40(8):765-772.
66. Pihusch M, Pihusch R, Fraunberger P, et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoi-etic stem cell recipients. Eur J Haematol. 2006; 76(2):93-101.
67. Uguccioni M, Meliconi R, Nesci S, et al. Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood. 1993;81(9):2252-2256.
68. Mohty M, Blaise D, Faucher C, et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning alloge-neic stem cell transplantation. Blood. 2005; 106(13):4407-4411.
69. Hori T, Naishiro Y, Sohma H, et al. CCL8 is a po-tential molecular candidate for the diagnosis of graft-versus-host disease. Blood. 2008;111(8): 4403-4412.
70. Piper KP, Horlock C, Curnow SJ, et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood. 2007;110(12):3827- 3832.
71. Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E. Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant. 2001;28(2): 197-200.
72. Luft T, Conzelmann M, Benner A, et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood. 2007;110(13):4535-4542.
73. Reddy P, Sun Y, Toubai T, et al. Histone deacety-lase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest. 2008;118(7):2562-2573.
74. Landfried K, Zhu W, Waldhier MC, et al. Trypto-phan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2, 3-dioxygenase. Blood. 2011;118(26):6971-6974.
75. Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothe-lial system. Blood. 2011;118(6):1685-1692.
76. Rezvani AR, Storer BE, Storb RF, et al. Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17(11):1594-1601.
77. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007;109(12):5511-5519.
78. Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012;119(12):2960-2963.
79. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012;119(16):3854-3860.
80. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22(5):485-502.
81. Pepe MS, Etzioni R, Feng Z, et al. Phases of bio-marker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054-1061.
82. Martin PJ, Rizzo JD, Wingard JR, et al. First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012; 18(8):1150-1163.
83. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res. 2009;15(6):1898-1905.
84. Paczesny S, Braun T, Lugt MV, et al. Three bio-marker panel at day 7 and 14 can predict development of grade II-IV acute graft-versus-host disease [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):675.
85. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113(13):2888-2894.
86. Martin P, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76(8): 1464-1472.
87. Sullivan KM, Mori M, Sanders J, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant. 1992; 10(Suppl 1):127-134.
88. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
89. Griffith LM, Pavletic SZ, Lee SJ, Martin PJ, Schultz KR, Vogelsang GB. Chronic graft-versus-host disease: implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant. 2008;14(4): 379-384.
90. Liem LM, van Lopik T, van Houwelingen HC, Aarden L, Goulmy E. Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood. 1998;91(4):1464-1468.
91. Fujimori Y, Takatsuka H, Takemoto Y, et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2000; 109(3):652-657.